Skip to Content

'
Kirk S. Culotta, Pharm.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2003 Xavier University, New Orleans, LA, PHARMD, Magna Cum Laude, Pharmacy
1995 University of New Orleans, New Orleans, LA, BS, Biological Sciences

Postgraduate Training

2003-2005 Clinical Fellowship, Pharmacology, The University of Texas MD Anderson Cancer Center, Houston, TX, Dr. Timothy Madden

Experience/Service

Other Appointments/Responsibilities

Clinical Pharmacy Specialist, CTRC, The University of Texas MD Anderson Cancer Center,Department of Pharmacology Research, Division of Pharmacy, Houston, TX, 2005-2010

Institutional Committee Activities

Member, MD Anderson Cancer Center Clinical Research Committee, 2006-present
Member, MD Anderson Cancer Center Clinical & Translational Research Center Steering Committee, 2006-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, El-Naggar AK, Wistuba I, Culotta KS, Mao L, Gillenwater A, Sagesaka YM, Hong WK, Papadimitrakopoulou V. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila) 2(11):931-41, 11/2009. PMID: 19892663.

Abstracts
1. K. Culotta, R. Kurzrock, C. Stewart, V. Dorsey, D. Harleaux-Grant, M. Wyles, M. Kramer, Y. Zhang, T. Madden, and D. Karp. Emergence of oral targeted agents in early clinical development: experience at MD Anderson Cancer Center – Clinical and Translational Research Center. Proceedings of the 50th ASCO Annual Meeting. 6/2010.
2. H.D. Brooks, B. Glisson, B. Bekele, K. Culotta, L. Ginsberg, F. Johnson, C. Lu, A. Sabichi, H. Tran, and V. Papadimitrakopoulou. Phase II study of dasatinib in the treatment of head and neck squamous cell carcinoma. Proceedings of the 49th ASCO Annual Meeting. 5/2009.
3. K. Culotta, J. Covey, C. Schultz, M. Hollingshead, J. Carter, S. Borgel, C. Bonomi, J. Tomaszweski, M. Johansen, and T. Madden. Preclinical pharmacokinetic and comparative biodistribution studies of NSC 706744, NSC 724998, and NSC 725776, three novel indenoisoquinoline topoisomerase I poisons, in CD2F1 mice. Proceedings of the 99th AACR Annual Meeting, 4/2008.
4. K. Culotta, D. Kirkpatrick, J. Covey, C. Schultz, D. Mack, R. Rhea, T. Allen, G. Powis, M. Johansen, and T. Madden. Preclinical pharmacokinetic and comparative biodistribution studies of PX-866, a broad spectrum phospha-tidylinositol-3-kinase (PI-3K) inhibitor, in F344 rats. Proceedings of the 18th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics, 11/2006.

Last updated: 2/1/2011